Sandu Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021
For the nine months, sales was INR 540.77 million compared to INR 446.6 million a year ago. Revenue was INR 541.32 million compared to INR 448.23 million a year ago. Net income was INR 13.2 million compared to INR 7.28 million a year ago. Basic earnings per share from continuing operations was INR 1.67 compared to INR 1.03 a year ago. Diluted earnings per share from continuing operations was INR 1.47 compared to INR 1.03 a year ago.